Brief: MEI Pharma Begins Evaluation Of Strategic Alternatives
30/07/2024 22:42
July 30 (Reuters) - MEI Pharma Inc MEIP.O :
* MEI PHARMA INC: BOARD DETERMINED TO BEGIN EVALUATION OF
STRATEGIC ALTERNATIVES
* MEI PHARMA INC: INTENDED TO PROMPTLY DISCONTINUE CLINICAL
DEVELOPMENT OF VORUCICLIB
* MEI PHARMA INC: CONTINUING TO CONDUCT CERTAIN NON-CLINICAL
ACTIVITIES RELATED TO CO'S DRUG CANDIDATE ASSETS
Source text for Eikon: ID:n0000950170-24-087841
Further company coverage: MEIP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lite Strategy
See all newsBrief: Lite Strategy Receives Governance Rights And Option To Buy Litvm Future Network Tokens
U.S. RESEARCH ROUNDUP- Equinix, KLA, WW Grainger
Brief: Lite Strategy Inc - On Nov 14, Board Approves Justin J. File As Permanent CEO - SEC Filing
Brief: Lite Strategy Reports First Quarter Fiscal Year 2026 Results Highlights Successful Launch Of $100M Litecoin Treasury Strategy And Movement Into Active Capital Market Operations
Brief: Lite Strategy Announces $25M Share Repurchase Program, Signaling Shift From Initial Litecoin Accumulation To Active Capital Market Operations